Prevalence and predictors of diagnosed mild cognitive impairment among Medicare beneficiaries

Elyse Couch1, Munachimso Ugoh1, Lauren Thomas1

  • 1Department of Health Services, Policy and Practice Brown University School of Public Health Providence Rhode Island USA.

Abstract

Insights

Only 10.6% of Medicare beneficiaries with mild cognitive impairment (MCI) symptoms receive a diagnosis. Women and those with higher education were more likely to be diagnosed, highlighting a need for improved MCI detection rates.

Area of Science:

  • Gerontology
  • Neurology
  • Public Health

Background:

  • Mild cognitive impairment (MCI) is a significant risk factor for dementia.
  • Early diagnosis of MCI allows for timely intervention and planning.
  • MCI diagnosis rates among Medicare beneficiaries remain largely unknown.

Purpose of the Study:

  • To determine the prevalence of diagnosed MCI among Medicare beneficiaries.
  • To identify factors associated with MCI diagnosis in this population.

Main Methods:

  • Utilized data from the National Health and Aging Trends Study (NHATS) linked with Medicare claims (2014-2022).
  • Defined MCI using an NHATS algorithm and identified diagnoses via ICD codes.
  • Employed logistic regression to analyze predictors of MCI diagnosis.

Main Results:

  • 10.6% of Medicare beneficiaries with MCI symptoms had a recorded MCI diagnosis.
  • Higher odds of diagnosis were observed in women and those with a bachelor's degree or higher.
  • Lower odds of diagnosis were associated with attending doctor visits alone.

Conclusions:

  • Current MCI diagnosis rates among Medicare beneficiaries are low.
  • Targeted strategies are essential to enhance MCI detection.
  • Improved diagnosis is critical given advancements in MCI therapies and diagnostics.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
740
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
482
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
503
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
206